Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy https://www.biorxiv.org/content/10.1101/2023.04.03.535467v1?med=mas
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy https://www.biorxiv.org/content/10.1101/2023.04.03.535467v1?med=mas